



Terveydenhuollon toimijoiden kanssa tehdyn yhteistyön rahanarvoiset edut

Viatrix Oy:n (entisten Mylan Finland Oy:n ja Meda Oy:n) etuuskien julkistamisraportissa ja sen muistiossa raportoidaan tämän yhtiön ja terveydenhuollon toimijoiden väliseen yhteistyöhön liittyvät rahanarvoiset edut.

Vuosi 2020

Meda Oy Terveydenhuollon ammattilaiset

Meda Oy Terveydenhuollon organisaatiot

Meda Oy Tapahtumat

Meda Oy Potilasjärjestöt

Mylan Finland Oy Terveydenhuollon ammattilaiset

Mylan Finland Oy Terveydenhuollon organisaatiot

Mylan Finland Oy Tapahtumat

Mylan Finland Oy Potilasjärjestöt

Muistio julkistamisraporttiin

Transfers of Value to HCPs for fees for service and consultancy

Company:		Date of disclosure:	24.6.2021	
Name of HCP	HCP's principle place of business	Unique Identifier (if relevant)	Type of fees for services and consultancy	Aggregated Amount / Value of ToV
Aggregated number of recipients included in the aggregate disclosure 1			Fee for services, speaker and consultancy	6600

Transfer of Value to Healthcare Organisations

Company:	Meda Oy		Date of disclosure:	24.6.2021
Name of HCO	HCO's principal place of business	Category of ToV	Purpose / Description of ToV	Aggregated Amount / Value of ToV
Itä-Suomen yliopisto	Kuopio	Sponsorship	fee for services / consultancy	1300

Transfers of Value to HCPs for meetings, educational support, and site visits: Option 1

Company:	Meda Oy				Date of disclosure:	24.6.2021		
Name of HCP	HCP's principal place of business	Unique Identifier (if relevant)	Number of Third Party Organised Conferences			Number of Company Organised Meetings / Site Visits		
			Domestic	European	International	Domestic	European	International
Aggregated number of recipients included in the aggregate disclosure:								

Transfer of Value to Patient Organisations

Company:	Meda Oy	Date of disclosure:	24.6.2021
Name of Patient Organisation	Category of ToV	Purpose / Description of TOV	Aggregated Amount / Value of TOV

Transfers of Value to HCPs for fees for service and consultancy

Company:	Mylan Finland Oy		Date of disclosure:	24.6.2021
Name of HCP	HCP's principle place of business	Unique Identifier (if relevant)	Type of fees for services and consultancy	Aggregated Amount / Value of ToV
Karlsson Paula	Hollola	WFIR00040641	Fee for services	1305,7
Korpela Martti	Helsinki	WFIM00008835	Fee for services	4100
Mikkola Tomi	Helsinki	WFIM00014887	Fee for services	1473,65
Molander Pauliina	Helsinki	WFIM00015558	Fee for services	1000
Murto Pirjo	Helsinki	WFIR00040037	Fee for services	400
Mälkönen Tarja	Helsinki	WFIM00015023	Fee for services	1200
Salo-Hartikainen Soile	Vantaa	WFIR00040043	Fee for services	400
Seppälä Niko	Pori	WFIM00013450	Fee for services	7950
Tuompo Riitta	Helsinki	WFIM00012515	Fee for services	1000
Aggregated number of recipients included in the aggregate disclosure: 2			Fee for services	19489,5

Transfer of Value to Healthcare Organisations

Company:	Mylan Finland Oy		Date of disclosure:	24.6.2021
Name of HCO	HCO's principal place of business	Category of ToV	Purpose / Description of ToV	Aggregated Amount / Value of ToV
Hämeen Apteekkariyhdistys	Nokia	Sponsorship	Sponsorship	1777

Transfers of Value to HCPs for meetings, educational support, and site visits: Option 2

Company:	Mylan Finland Oy	Date of disclosure:	24.6.2021
Category	Name of Congress	Number of HCP recipients	Aggregate support to HCPs for Meetings, Educational Support and Site Visits
Third Party Organised Congress	UEGW, Virtual congress 11.-13.10.2020	3	799
	ESMO, Virtual congress 19.-21.9.2021	2	474

Transfer of Value to Patient Organisations

Company:	Mylan Finland Oy	Date of disclosure:	24.6.2021
Name of Patient Organisation	Category of ToV	Purpose / Description of TOV	Aggregated Amount / Value of TOV

Methodological note with regards to Transfers of Value (ToV) to Healthcare Professionals (HCP), Healthcare Organizations (HCO) and Patient Organizations, during the calendar year 2020.

This methodological note applies to following Viatris legal entities registered in Finland: Mylan Finland Oy and Meda Oy – hereinafter referred to as “Viatris”.

Introduction and scope

The basis for publishing the Disclosure for ToV is in Medicines for Europe Code of Conduct on Interactions with the Healthcare Community, published February 2015 and updated January 2016, as defined by the code as a rule of membership of the trade association. This Disclosure concerns the calendar year 2020. ToV can be provided by Viatris to HCPs, HCOs and Patient organizations either as payment for services (use of HCPs or HCOs as scientific consultants) or payment for support memberships of non-profit Patient organizations. They can also be provided indirectly by third parties in the form of accommodation, travel or registration fee for HCPs to attend scientific educational events. The consulting payments include the collaboration on Patient support programs. Subsistence of Viatris’s own personnel does not fall under the scope of Finnish Generics Medicines Association (Rinnakkaislääketeollisuus ry) requirements for Disclosure and therefore it has been left out of the scope.

Data collection

Payments made to HCPs, HCOs and Patient organizations during calendar year 2020 were collected from Viatris’s internal financial systems and internal tracking processes. Names and addresses were collected as per the location of workplace and matched with IMS OneKey database information. Consent to disclose ToV provided to HCPs had been requested from the HCPs as a part of contract work, with the option to refuse the publication of HCP name. However, due to the COVID-19 pandemic business continuity situation, Viatris has disclosed the monetary benefits of the healthcare professional concerned as an aggregate value, regardless of whether HCPs have given their consent to publish their names or not, as per the guidance which came out from Medicines for Europe in May 2020.

Date used for data provision

For direct payments, the date when transaction was made, is the date provided for collection of ToV. For indirect payments, for instance conferences, where travel, accommodation and hospitality were provided, the date of conference, meeting or other event, is captured as the date of ToV in Viatris reporting tool.

Treatment of value added tax (VAT)

Viatris reports ToV as net value, without VAT.

Cross-border payments

Viatriis operates internationally and therefore cross-border payments need to be considered in ToV payments reporting. Viatriis's data reporting tool allows cross-border payments to be reported to the country of HCP's permanent address.

Education of HCPs through HCOs

When Viatriis provides HCPs with ToV through providing scientific education through HCOs or teaching institutions, the ToV is disclosed in the HCP support aggregate and not the HCO to avoid duplicate reporting.

Multi-year contracts

There are four multi-year contracts with HCPs to disclose in 2020. All four HCPs have been contracted for consulting services. The ToV is disclosed under HCP documentation or HCP support aggregate in instances where the HCP has not provided consent for disclosure.

Support Memberships

Viatriis provides support for non-profit Healthcare Organizations (HCO) in order to support science and education for genuine philanthropic and charitable purposes. Contributions are provided to recognized charities, civic organisations, not for-profit institutions which have charitable or philanthropic objectives as their main purpose, and/or community and charitable initiatives, but never to for-profit entities. Contributions are given for the purpose of supporting scientific research, medical education, patient education, patient access to healthcare, or the overall development of healthcare systems. This support is reported under ToV for HCO documentation.